Cardioxane

Cardioxane (Dexrazoxane) is an intravenous medication used to reduce heart damage from certain chemotherapy treatments. It is manufactured by Cnx Therapeutics Ireland Limited and is available in the EU.

Cardioxane is primarily used to protect the heart from damage caused by specific chemotherapy drugs. It is often administered to patients undergoing treatments that may have cardiotoxic effects. The medication helps to mitigate the risk of heart-related side effects, making it a valuable adjunct in cancer therapy.

Cardioxane works by interfering with the toxic effects of chemotherapy on heart cells. Common effects may include a reduction in the severity of heart-related side effects, allowing patients to continue their cancer treatment with a lower risk of cardiovascular complications.

Cardioxane should be administered under the supervision of a healthcare professional. It is important to follow the prescribed dosage and administration guidelines to ensure safety and effectiveness. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

Cardioxane may interact with other medications, particularly those metabolized by the liver. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of Cardioxane.